OUTCOME OF PROTON PUMP INHIBITOR CO-ADMINISTRATION WITH DUALANTIPLATELET THERAPY IN THE MANAGEMENT OF ATHEROSCLEROTICCARDIOVASCULAR DISEASE: A RETROSPECTIVE REAL-WORLD STUDY
试验速览
- 阶段
- 不适用
- 状态
- Other
- 入组人数
- 511
- 试验地点
- 3
- 主要终点
- The outcome of co administration of various currently used
研究概览
简要总结
This is an EMR based retrospective, observational, longitudinal, multicenter real-world studydesigned to analyze the data from inpatient and outpatient settings up to 10-15 healthcare centersacross various regions of India. The anonymized medical records with follow up visits data of 12months at baseline, follow-up visit 1 (3 ± 1 month), follow-up visit 2 (6 ± 1 month), follow-upvisit 3 (9 ± 1 month) and after 12 months (12 ± 1 month) will be taken into consideration. Theanonymized data of ASCVD patients on co-administration of various currently used PPIs withdual antiplatelet therapy will be considered for the analysis and all concomitants medication willbe reported as available in database / medical records
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •Patients with documented history of atherosclerotic cardiovascular disease using dual antiplatelet drugs along with PPIs.
排除标准
- •Patients with a history of peptic ulcer or gastric or duodenal surgery Patients with erosive esophagitis and gastric-outlet obstruction Patients treated with multiple anti-ulcer medications Patients with severe pulmonary, hepatic, or renal disease Patients with incomplete records Patients on anticoagulants other than aspirin plus clopidogrel and on PPIs other than rabeprazole, pantoprazole and esomeprazole.
结局指标
主要结局
The outcome of co administration of various currently used
时间窗: Baseline to end of 12 months
cardiovascular related illness
时间窗: Baseline to end of 12 months
intervention or coronary artery bypass grafting
时间窗: Baseline to end of 12 months
Death Bleeding events Stent thrombosis
时间窗: Baseline to end of 12 months
PPIs with dual antiplatelet therapy in
时间窗: Baseline to end of 12 months
patients of atherosclerotic cardiovascular
时间窗: Baseline to end of 12 months
Repeat percutaneous coronary
时间窗: Baseline to end of 12 months
disease will be analyzed in terms of percentage of Myocardial infarction Stroke Unstable angina Heart failure Rehospitalization for
时间窗: Baseline to end of 12 months
次要结局
- The outcome of(co administration of rabeprazole vs other)